Physician profile
Deval Mehta
NPI 1437376795
$5,899.17
in general payments reported to CMS, 2019-2025
37 companies · $813 in 2025
The $813 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $444 · 2021: $745 · 2022: $1,215 · 2023: $594 · 2024: $1,563 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097 · Travel and Lodging: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.79 |
| Travel and Lodging | $872.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,760.47 | 2019-2025 | Xact, Acculink, Mitraclip |
| Pfizer INC. | $608.08 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $550.86 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $338.73 | 2019-2023 | Xarelto |
| Philips North America LLC | $314.08 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Az7) Lasers |
| Astrazeneca Pharmaceuticals Lp | $276.69 | 2020-2025 | Farxiga, Lokelma |
| Cook Medical LLC | $266.56 | 2019-2023 | Zilver Ptx |
| Amarin Pharma, INC. | $263.94 | 2019-2022 | |
| Amgen INC. | $209.22 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $180.95 | 2021-2025 | Verquvo |
| Biotronik INC. | $171.29 | 2019-2022 | |
| Abiomed | $125.92 | 2019-2025 | Impella |
| Medtronic, INC. | $96.04 | 2022-2025 | Symplicity G3 |
| Sanofi-Aventis U.S. LLC | $81.60 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $71.11 | 2024-2025 | Opsumit, Opsynvi |
Show all 36 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$349,694.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deval Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.